Showing results (261-270 of 395) with videos related to
Sort By:
Pageof 40
Blood|December 1, 2005
Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational statusMia Thorsélius, Alexander Kröber, Fiona Murray, et al.Blood|June 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialArmin Riecke, Sandra Robrecht, Deyan Yordanov Yosifov, et al.The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.Haematologica|October 15, 2020
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Eugen Tausch, Philipp Beck, Richard F Schlenk, et al.Blood|October 11, 2012
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterationsJennifer Edelmann, Karlheinz Holzmann, Florian Miller, et al.Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma NetworkEva Hoster, Wolfram Klapper, Olivier Hermine, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jirí Mayer, et al.The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.Haematologica|November 10, 2018
The involvement of microRNA in the pathogenesis of Richter syndromeKatrien Van Roosbroeck, Recep Bayraktar, Steliana Calin, et al.Pageof 40